Cargando…
Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer
AIM: We aimed to evaluate the efficacy and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression in unresectable pancreatic cancer. METHODS: The expression of BRCA1 mRNA in tumor tissues of 25 patients with pancreatic cancer was detected in this...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663848/ https://www.ncbi.nlm.nih.gov/pubmed/36387089 http://dx.doi.org/10.3389/fonc.2022.1015232 |
_version_ | 1784830972155396096 |
---|---|
author | Du, Juan Zhu, Linxi Sha, Huizi Zou, Zhengyun Shen, Jie Kong, Weiwei Zhao, Lianjun Gu, Qing Yu, Lixia Qiu, Yudong Liu, Baorui |
author_facet | Du, Juan Zhu, Linxi Sha, Huizi Zou, Zhengyun Shen, Jie Kong, Weiwei Zhao, Lianjun Gu, Qing Yu, Lixia Qiu, Yudong Liu, Baorui |
author_sort | Du, Juan |
collection | PubMed |
description | AIM: We aimed to evaluate the efficacy and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression in unresectable pancreatic cancer. METHODS: The expression of BRCA1 mRNA in tumor tissues of 25 patients with pancreatic cancer was detected in this retrospective study. Patients in the medium and high expression groups were treated with paclitaxel-based chemotherapy: albumin paclitaxel 125mg/m(2), gemcitabine 1g/m(2), day 1. Patients in the low expression group were treated with oxaliplatin-based chemotherapy: oxaliplatin 85mg/m(2), gemcitabine 1g/m(2), day 1. Sequential GM-CSF and IL-2 immunotherapy were applied. Patient condition, treatment efficacy and safety were assessed every 4 cycles. RESULTS: A total of 25 patients were enrolled in the study. All of them were observed for toxic side effects and 24 of them were evaluated for efficacy. The median overall survival and median progression-free survival were 11.9 months and 6.3 months. The disease control rate was 91.7%, of which 37.5% (9/24) patients achieved partial remission (PR), 54.2% (13/24) patients achieved stable disease (SD) and 8.3% (2/24) patients were assessed as progressive disease(PD). Of the 15 patients with medium or high expression in BRCA1 mRNA, 7 achieved PR and 8 achieved SD. Of the 9 patients with low BRCA1 mRNA expression, 2 achieved PR, 5 achieved SD and 2 had PD. The proportion of eosinophils in the blood of some patients with good therapeutic effects was significantly higher than that before treatment. Hematological and non-hematological toxicity during the treatment were mostly grade 1~2. The two most common grade 3 to 4 adverse events were fever and thrombocytopenia. CONCLUSION: Our results suggest that individualized selection of chemotherapy combined with sequential immunotherapy according to BRCA1 mRNA expression level in unresectable pancreatic cancer could control the disease and have controllable adverse reactions. |
format | Online Article Text |
id | pubmed-9663848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96638482022-11-15 Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer Du, Juan Zhu, Linxi Sha, Huizi Zou, Zhengyun Shen, Jie Kong, Weiwei Zhao, Lianjun Gu, Qing Yu, Lixia Qiu, Yudong Liu, Baorui Front Oncol Oncology AIM: We aimed to evaluate the efficacy and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression in unresectable pancreatic cancer. METHODS: The expression of BRCA1 mRNA in tumor tissues of 25 patients with pancreatic cancer was detected in this retrospective study. Patients in the medium and high expression groups were treated with paclitaxel-based chemotherapy: albumin paclitaxel 125mg/m(2), gemcitabine 1g/m(2), day 1. Patients in the low expression group were treated with oxaliplatin-based chemotherapy: oxaliplatin 85mg/m(2), gemcitabine 1g/m(2), day 1. Sequential GM-CSF and IL-2 immunotherapy were applied. Patient condition, treatment efficacy and safety were assessed every 4 cycles. RESULTS: A total of 25 patients were enrolled in the study. All of them were observed for toxic side effects and 24 of them were evaluated for efficacy. The median overall survival and median progression-free survival were 11.9 months and 6.3 months. The disease control rate was 91.7%, of which 37.5% (9/24) patients achieved partial remission (PR), 54.2% (13/24) patients achieved stable disease (SD) and 8.3% (2/24) patients were assessed as progressive disease(PD). Of the 15 patients with medium or high expression in BRCA1 mRNA, 7 achieved PR and 8 achieved SD. Of the 9 patients with low BRCA1 mRNA expression, 2 achieved PR, 5 achieved SD and 2 had PD. The proportion of eosinophils in the blood of some patients with good therapeutic effects was significantly higher than that before treatment. Hematological and non-hematological toxicity during the treatment were mostly grade 1~2. The two most common grade 3 to 4 adverse events were fever and thrombocytopenia. CONCLUSION: Our results suggest that individualized selection of chemotherapy combined with sequential immunotherapy according to BRCA1 mRNA expression level in unresectable pancreatic cancer could control the disease and have controllable adverse reactions. Frontiers Media S.A. 2022-11-01 /pmc/articles/PMC9663848/ /pubmed/36387089 http://dx.doi.org/10.3389/fonc.2022.1015232 Text en Copyright © 2022 Du, Zhu, Sha, Zou, Shen, Kong, Zhao, Gu, Yu, Qiu and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Du, Juan Zhu, Linxi Sha, Huizi Zou, Zhengyun Shen, Jie Kong, Weiwei Zhao, Lianjun Gu, Qing Yu, Lixia Qiu, Yudong Liu, Baorui Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer |
title | Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer |
title_full | Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer |
title_fullStr | Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer |
title_full_unstemmed | Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer |
title_short | Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer |
title_sort | therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on brca1 mrna expression level in unresectable pancreatic cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663848/ https://www.ncbi.nlm.nih.gov/pubmed/36387089 http://dx.doi.org/10.3389/fonc.2022.1015232 |
work_keys_str_mv | AT dujuan therapeuticeffectandsafetyofindividualizedchemotherapycombinedwithsequentialimmunotherapybasedonbrca1mrnaexpressionlevelinunresectablepancreaticcancer AT zhulinxi therapeuticeffectandsafetyofindividualizedchemotherapycombinedwithsequentialimmunotherapybasedonbrca1mrnaexpressionlevelinunresectablepancreaticcancer AT shahuizi therapeuticeffectandsafetyofindividualizedchemotherapycombinedwithsequentialimmunotherapybasedonbrca1mrnaexpressionlevelinunresectablepancreaticcancer AT zouzhengyun therapeuticeffectandsafetyofindividualizedchemotherapycombinedwithsequentialimmunotherapybasedonbrca1mrnaexpressionlevelinunresectablepancreaticcancer AT shenjie therapeuticeffectandsafetyofindividualizedchemotherapycombinedwithsequentialimmunotherapybasedonbrca1mrnaexpressionlevelinunresectablepancreaticcancer AT kongweiwei therapeuticeffectandsafetyofindividualizedchemotherapycombinedwithsequentialimmunotherapybasedonbrca1mrnaexpressionlevelinunresectablepancreaticcancer AT zhaolianjun therapeuticeffectandsafetyofindividualizedchemotherapycombinedwithsequentialimmunotherapybasedonbrca1mrnaexpressionlevelinunresectablepancreaticcancer AT guqing therapeuticeffectandsafetyofindividualizedchemotherapycombinedwithsequentialimmunotherapybasedonbrca1mrnaexpressionlevelinunresectablepancreaticcancer AT yulixia therapeuticeffectandsafetyofindividualizedchemotherapycombinedwithsequentialimmunotherapybasedonbrca1mrnaexpressionlevelinunresectablepancreaticcancer AT qiuyudong therapeuticeffectandsafetyofindividualizedchemotherapycombinedwithsequentialimmunotherapybasedonbrca1mrnaexpressionlevelinunresectablepancreaticcancer AT liubaorui therapeuticeffectandsafetyofindividualizedchemotherapycombinedwithsequentialimmunotherapybasedonbrca1mrnaexpressionlevelinunresectablepancreaticcancer |